secwatch / observer
8-K filed January 4, 2024, 6:59 PM ET ticker AXSM CIK 0001579428
earnings confidence high sentiment neutral materiality 0.75

Axsome reports preliminary Q4 net product revenue of $71M; full year $204M

Axsome Therapeutics, Inc.

2023-FY EPS reported -$5.27 revenue$270,600,000
item 2.02item 8.01item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axsome Therapeutics, Inc. reported the full year of 2023 results: revenue $204 million.

Period
the full year of 2023
Revenue
$204 million
Result
preliminary results
Exact text from the filing
Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of 2023, respectively.
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axsome Therapeutics, Inc. reported the fourth quarter of 2023 results: revenue $71 million.

Period
the fourth quarter of 2023
Revenue
$71 million
Result
preliminary results
Exact text from the filing
Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of 2023, respectively.
View on SEC.gov

Browse all earnings releases →

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0000950170-24-001488
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.